Yael Ben-Haim

Dr. Yael Ben-Haim

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2021 in European Heart Journal
Verified
Journal Article
Closed access
EBElijah R Behr
Elijah R Behr
YBYael Ben-Haim
Yael Ben-Haim
MAMichael J Ackerman
Michael J Ackerman
AKAndrew D Krahn
Andrew D Krahn
AWArthur A M Wilde
Arthur A M Wilde
Brugada syndrome (BrS) was first described as a primary electrical disorder predisposing to the risk of sudden cardiac death and characterized by right precordial lead ST elevation. Early description of right ventricular structural abnormalities and of right ventricular outflow tract (RVOT) conduction delay in BrS patients set the stage for the current controversy over the pathophysiology underlying the syndrome: channelopathy or cardiomyopathy; repolarization or depolarization. This review examines the current understanding of the BrS substrate, its genetic and non-genetic basis, theories of pathophysiology, and the clinical implications thereof. We propose that the final common pathway for BrS could be viewed as a disease of ‘reduced RVOT conduction reserve’.

16 February 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
BABabken Asatryan
Babken Asatryan
LYLauren Yee
Lauren Yee
YBYael Ben-Haim
Yael Ben-Haim
SDStephan Dobner
Stephan Dobner
HSHelge Servatius
Helge Servatius
AKAndrew D. Krahn
Andrew D. Krahn
Sex-related differences in prevalence, clinical presentation, and outcome of cardiac channelopathies are increasingly recognized, despite their autosomal transmission and hence equal genetic predisposition among sexes. In congenital long-QT syndrome, adult women carry a greater risk for Torsades de pointes and sudden cardiac death than do men. In contrast, Brugada syndrome is observed predominantly in adult men, with a considerably higher risk of arrhythmic sudden cardiac death in adult men than in women. In both conditions, the risk for arrhythmias varies with age. Sex-associated differences appear less evident in other cardiac channelopathies, likely a reflection of their rare(r) occurrence and our limited knowledge. In several cardiac channelopathies, sex-specific predictors of outcome have been identified. Together with genetic and environmental factors, sex hormones contribute to the sex-related disparities in cardiac channelopathies through modulation of the expression and function of cardiac ion channels. Despite these insights, essential knowledge gaps exist in the mechanistic understanding of these differences, warranting further investigation. Precise application of the available knowledge may improve the individualized care of patients with cardiac channelopathies. Promoting the reporting of sex-related phenotype and outcome parameters in clinical and experimental studies and advancing research on cardiac channelopathy animal models should translate into improved patient outcomes. This review provides a critical digest of the current evidence for sex-related differences in cardiac channelopathies and emphasizes their clinical implications and remaining gaps requiring further research.

Verified
Journal Article
Open access
PDF file
POPaz Ovics
Paz Ovics
DRDanielle Regev
Danielle Regev
PBPolina Baskin
Polina Baskin
MDMor Davidor
Mor Davidor
YSYuval Shemer
Yuval Shemer
Ofer BinahOfer Binah
Ofer Binah
Over the years, numerous groups have employed human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) as a superb human-compatible model for investigating the function and dysfunction of cardiomyocytes, drug screening and toxicity, disease modeling and for the development of novel drugs for heart diseases. In this review, we discuss the broad use of iPSC-CMs for drug development and disease modeling, in two related themes. In the first theme—drug development, adverse drug reactions, mechanisms of cardiotoxicity and the need for efficient drug screening protocols—we discuss the critical need to screen old and new drugs, the process of drug development, marketing and Adverse Drug reactions (ADRs), drug-induced cardiotoxicity, safety screening during drug development, drug development and patient-specific effect and different mechanisms of ADRs. In the second theme—using iPSC-CMs for disease modeling and developing novel drugs for heart diseases—we discuss the rationale for using iPSC-CMs and modeling acquired and inherited heart diseases with iPSC-CMs.

17 November 2020 in EP Europace
Verified
Journal Article
Closed access
YBYael Ben-Haim
Yael Ben-Haim
AAAngeliki Asimaki
Angeliki Asimaki
EBElijah R Behr
Elijah R Behr
Arrhythmogenic cardiomyopathy (ACM) and Brugada syndrome (BrS) are inherited diseases characterized by an increased risk for arrhythmias and sudden cardiac death. Possible overlap between the two was suggested soon after the description of BrS. Since then, various studies focusing on different aspects have been published pointing to similar findings in the two diseases. More recent findings on the structure of the cardiac cell–cell junctions may unite the pathophysiology of both diseases and give further evidence to the theory that they may in part be variants of the same disease spectrum. In this review, we aim to summarize the studies indicating the pathophysiological, genetic, structural, and electrophysiological overlap between ACM and BrS.
1

21 May 2024 in Circulation
Verified
Journal Article
Open access
BEBode Ensam
Bode Ensam
CSChiara Scrocco
Chiara Scrocco
DJDavid Johnson
David Johnson
YWYanushi D. Wijeyeratne
Yanushi D. Wijeyeratne
RBRachel Bastiaenen
Rachel Bastiaenen
EBElijah R. Behr
Elijah R. Behr

8 April 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
CSChiara Scrocco
Chiara Scrocco
YBYael Ben-Haim
Yael Ben-Haim
BEBode Ensam
Bode Ensam
RARobert Aldous
Robert Aldous
MTMaite Tome-Esteban
Maite Tome-Esteban
EBElijah R Behr
Elijah R Behr
Brugada syndrome (BrS) diagnosis and risk stratification rely on the presence of a spontaneous type 1 (spT1) electrocardiogram (ECG) pattern; however, its spontaneous fluctuations may lead to misdiagnosis and risk underestimation. This study aims to assess the role for repeat high precordial lead (HPL) resting and ambulatory ECG monitoring in identifying a spT1, and evaluate its prognostic role. HPL resting and ambulatory monitoring ECGs of BrS subjects were reviewed retrospectively, and the presence of a spT1 associated with ventricular dysrhythmias and sudden cardiac death (SCD). Three-hundred and fifty-eight subjects (77 with spT1 pattern at presentation, Group 1, and 281 without, Group 2) were included. In total, 1651 resting HPL resting and 621 ambulatory monitoring ECGs were available for review, or adequately described. Over a median follow-up of 72 months (interquartile range - IQR - 75), 42/77 (55%) subjects in Group 1 showed a spT1 in at least one ECG. In Group 2, 36/281 subjects (13%) had a newly detected spT1 (1.9 per 100 person-year) and 23 on an HPL ambulatory recording (8%). Seven previously asymptomatic subjects, five of whom had a spT1 (four at presentation and one at follow-up), experienced arrhythmic events; survival analysis indicated that a spT1, either at presentation or during lifetime, was associated with events. Univariate models showed that a spT1 was consistently associated with increased risk [spT1 at presentation: hazard ratio (HR) 6.3, 95% confidence interval (CI) 1.4–28, P = 0.016; spT1 at follow-up: HR 3.1, 95% CI 1.3–7.2, P = 0.008]. Repeated ECG evaluation and HPL ambulatory monitoring are vital in identifying transient spT1 Brugada pattern and its associated risk. The implications of high precordial 12-lead resting and ambulatory ECG monitoring for Brugada syndrome: the flow diagram indicates the patient cohort and selection according to the presence of a spontaneous type 1 (spT1) Brugada pattern on the ECG at initial assessment (Group 1) and then subsequently during follow-up with high precordial 12-lead resting and ambulatory ECG monitoring (Group 2). Arrhythmic event rates and hazard ratios (HRs) are given for asymptomatic patients from each group with a spT1 vs. never showing a spT1 at all.